How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1

Cytokine

Volumn 69, Issue 1, 2014, Pages 136-145

  Keyel, Peter A ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

Caspase 1; DAMP; Inflammasome; NLRP3

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 18; HMGB1 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; INTERLEUKIN 1BETA;

BACTERIAL INFECTION; CELLULAR IMMUNITY; COMPLEX FORMATION; CYTOKINE PRODUCTION; HOST PARASITE INTERACTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION; IMMUNOLOGY; SECRETION (PROCESS);

BACTERIA (MICROORGANISMS);

BACTERIAL INFECTIONS; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-1BETA; PARASITIC DISEASES; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 84904169449     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.03.007     Document Type: Review

References (204)

1. Dinarello C.A. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 2011, 41:1203-1217.
2. Carta S., Lavieri R., Rubartelli A. Different members of the IL-1 family come out in different ways: DAMPs vs. cytokines?. Front Immunol 2013, 4:123.
3. Dinarello C.A., Novick D., Kim S., Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol 2013, 4:289.
4. Dinarello C.A., Renfer L., Wolff S.M. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci USA 1977, 74:4624-4627.
5. Rosenwasser L.J., Dinarello C.A., Rosenthal A.S. Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med 1979, 150:709-714.
6. van de Veerdonk F.L., Netea M.G. New insights in the immunobiology of IL-1 family members. Front Immunol 2013, 4:167.
7. Miller A.C., Schattenberg D.G., Malkinson A.M., Ross D. Decreased content of the IL1 alpha processing enzyme calpain in murine bone marrow-derived macrophages after treatment with the benzene metabolite hydroquinone. Toxicol Lett 1994, 74:177-184.
8. Berda-Haddad Y., Robert S., Salers P., Zekraoui L., Farnarier C., Dinarello C.A., et al. Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1alpha. Proc Natl Acad Sci USA 2011, 108:20684-20689.
9. Kaplanski G., Farnarier C., Kaplanski S., Porat R., Shapiro L., Bongrand P., et al. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. Blood 1994, 84:4242-4248.
10. Lamkanfi M., Dixit V.M. Inflammasomes and their roles in health and disease. Ann Rev Cell Dev Biol 2012, 28:137-161.
11. Kapur V., Majesky M.W., Li L.L., Black R.A., Musser J.M. Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci USA 1993, 90:7676-7680.
12. Coeshott C., Ohnemus C., Pilyavskaya A., Ross S., Wieczorek M., Kroona H., et al. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci USA 1999, 96:6261-6266.
13. Schonbeck U., Mach F., Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998, 161:3340-3346.
14. van de Veerdonk F.L., Netea M.G., Dinarello C.A., Joosten L.A. Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 2011, 32:110-116.
15. Mills K.H., Dungan L.S., Jones S.A., Harris J. The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol 2013, 93:489-497.
16. Bossaller L., Chiang P.I., Schmidt-Lauber C., Ganesan S., Kaiser W.J., Rathinam V.A., et al. Cutting edge: FAS (CD95) mediates noncanonical IL-1beta and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol 2012, 189:5508-5512.
17. Dinarello C.A., Fantuzzi G. Interleukin-18 and host defense against infection. J Infect Dis 2003, 187(Suppl 2):S370-S384.
18. Sedimbi S.K., Hagglof T., Karlsson M.C. IL-18 in inflammatory and autoimmune disease. Cell Mol Life Sci 2013, 70:4795-4808.
19. Robertson M.J., Mier J.W., Logan T., Atkins M., Koon H., Koch K.M., et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 2006, 12:4265-4273.
20. Lee J.K., Kim S.H., Lewis E.C., Azam T., Reznikov L.L., Dinarello C.A. Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci USA 2004, 101:8815-8820.
21. Netea M.G., Joosten L.A., Lewis E., Jensen D.R., Voshol P.J., Kullberg B.J., et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006, 12:650-656.
22. Zorrilla E.P., Sanchez-Alavez M., Sugama S., Brennan M., Fernandez R., Bartfai T., et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc Natl Acad Sci USA 2007, 104:11097-11102.
23. Soudja S.M., Ruiz A.L., Marie J.C., Lauvau G. Inflammatory monocytes activate memory CD8(+) T and innate NK lymphocytes independent of cognate antigen during microbial pathogen invasion. Immunity 2012, 37:549-562.
24. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001, 12:53-72.
25. Xu D., Trajkovic V., Hunter D., Leung B.P., Schulz K., Gracie J.A., et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol 2000, 30:3147-3156.
26. Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007, 220:60-81.
27. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
28. Bianchi M.E. HMGB1 loves company. J Leukoc Biol 2009, 86:573-576.
29. Tang D., Kang R., Livesey K.M., Kroemer G., Billiar T.R., Van Houten B., et al. High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011, 13:701-711.
30. Calogero S., Grassi F., Aguzzi A., Voigtlander T., Ferrier P., Ferrari S., et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999, 22:276-280.
31. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
32. Klune J.R., Dhupar R., Cardinal J., Billiar T.R., Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008, 14:476-484.
33. Huang H., Nace G.W., McDonald K.A., Tai S., Klune J.R., Rosborough B.R., et al. Hepatocyte specific HMGB1 deletion worsens the injury in liver ischemia/reperfusion: a role for intracellular HMGB1 in cellular protection. Hepatology 2013.
34. Yanai H., Matsuda A., An J., Koshiba R., Nishio J., Negishi H., et al. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc Natl Acad Sci USA 2013, 110:20699-20704.
35. Li G., Liang X., Lotze M.T. HMGB1: the central cytokine for all lymphoid cells. Front Immunol 2013, 4:68.
36. Garcia-Arnandis I., Guillen M.I., Gomar F., Pelletier J.P., Martel-Pelletier J., Alcaraz M.J. High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1beta in osteoarthritic synoviocytes. Arthritis Res Ther 2010, 12:R165.
37. Sha Y., Zmijewski J., Xu Z., Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008, 180:2531-2537.
38. Hreggvidsdottir H.S., Ostberg T., Wahamaa H., Schierbeck H., Aveberger A.C., Klevenvall L., et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009, 86:655-662.
39. Yang H., Lundback P., Ottosson L., Erlandsson-Harris H., Venereau E., Bianchi M.E., et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012, 18:250-259.
40. Venereau E., Casalgrandi M., Schiraldi M., Antoine D.J., Cattaneo A., De Marchis F., et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012, 209:1519-1528.
41. Keller M., Ruegg A., Werner S., Beer H.D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008, 132:818-831.
42. Lamkanfi M., Sarkar A., Vande Walle L., Vitari A.C., Amer A.O., Wewers M.D., et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 2010, 185:4385-4392.
43. Miao E.A., Rajan J.V., Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev 2011, 243:206-214.
44. Lupfer C., Kanneganti T.D. The expanding role of NLRs in antiviral immunity. Immunol Rev 2013, 255:13-24.
45. Fernandes-Alnemri T., Yu J.W., Datta P., Wu J., Alnemri E.S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009, 458:509-513.
46. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518.
47. Roberts T.L., Idris A., Dunn J.A., Kelly G.M., Burnton C.M., Hodgson S., et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009, 323:1057-1060.
48. Park S., Juliana C., Hong S., Datta P., Hwang I., Fernandes-Alnemri T., et al. The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity. J Immunol 2013, 191:4358-4366.
49. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
50. Harder J., Franchi L., Munoz-Planillo R., Park J.H., Reimer T., Nunez G. Activation of the Nlrp3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-kappa B activation but proceeds independently of TLR signaling and P2X7 receptor. J Immunol 2009, 183:5823-5829.
51. Keyel P.A., Roth R., Yokoyama W.M., Heuser J.E., Salter R.D. Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation. Toxins (Basel) 2013, 5:1105-1118.
52. Heid M.E., Keyel P.A., Kamga C., Shiva S., Watkins S.C., Salter R.D. Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J Immunol 2013, 191:5230-5238.
53. Wen H., Miao E.A., Ting J.P. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 2013, 39:432-441.
54. Kerur N., Veettil M.V., Sharma-Walia N., Bottero V., Sadagopan S., Otageri P., et al. IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. Cell Host Microbe 2011, 9:363-375.
55. Lamkanfi M., Dixit V.M. Modulation of inflammasome pathways by bacterial and viral pathogens. J Immunol 2011, 187:597-602.
56. Hornung V., Latz E. Critical functions of priming and lysosomal damage for NLRP3 activation. Eur J Immunol 2010, 40:620-623.
57. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
58. So A., De Meulemeester M., Pikhlak A., Yucel A.E., Richard D., Murphy V., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
59. McGonagle D., Tan A.L., Shankaranarayana S., Madden J., Emery P., McDermott M.F. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007, 66:1683-1684.
60. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. New Engl J Med 2006, 355:581-592.
61. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New Engl J Med 2007, 356:1517-1526.
62. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. New Engl J Med 2009, 360:2416-2425.
63. Abbate A., Salloum F.N., Vecile E., Das A., Hoke N.N., Straino S., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008, 117:2670-2683.
64. Jacobs C.A., Baker P.E., Roux E.R., Picha K.S., Toivola B., Waugh S., et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J Immunol 1991, 146:2983-2989.
65. Woldbaek P.R., Sande J.B., Stromme T.A., Lunde P.K., Djurovic S., Lyberg T., et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart C 2005, 289:H708-H714.
66. Raeburn C.D., Dinarello C.A., Zimmerman M.A., Calkins C.M., Pomerantz B.J., McIntyre R.C., et al. Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am J Physiol Heart C 2002, 283:H650-H657.
67. Lalor S.J., Dungan L.S., Sutton C.E., Basdeo S.A., Fletcher J.M., Mills K.H. Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol 2011, 186:5738-5748.
68. Banda N.K., Vondracek A., Kraus D., Dinarello C.A., Kim S.H., Bendele A., et al. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol 2003, 170:2100-2105.
69. Ten Hove T., Corbaz A., Amitai H., Aloni S., Belzer I., Graber P., et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001, 121:1372-1379.
70. Siegmund B., Fantuzzi G., Rieder F., Gamboni-Robertson F., Lehr H.A., Hartmann G., et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Reg I 2001, 281:R1264-R1273.
71. Brydges S.D., Broderick L., McGeough M.D., Pena C.A., Mueller J.L., Hoffman H.M. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest 2013, 123:4695-4705.
72. Andersson U., Tracey K.J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011, 29:139-162.
73. Kokkola R., Li J., Sundberg E., Aveberger A.C., Palmblad K., Yang H., et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003, 48:2052-2058.
74. Pullerits R., Jonsson I.M., Verdrengh M., Bokarewa M., Andersson U., Erlandsson-Harris H., et al. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum 2003, 48:1693-1700.
75. Uzawa A., Mori M., Taniguchi J., Masuda S., Muto M., Kuwabara S. Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clin Exp Immunol 2013, 172:37-43.
76. Robinson A.P., Caldis M.W., Harp C.T., Goings G.E., Miller S.D. High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis. J Autoimmun 2013, 43:32-43.
77. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
78. Sahoo M., Ceballos-Olvera I., del Barrio L., Re F. Role of the inflammasome, IL-1beta, and IL-18 in bacterial infections. Sci World J 2011, 11:2037-2050.
79. Strowig T., Henao-Mejia J., Elinav E., Flavell R. Inflammasomes in health and disease. Nature 2012, 481:278-286.
80. Miller L.S., Pietras E.M., Uricchio L.H., Hirano K., Rao S., Lin H., et al. Inflammasome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol 2007, 179:6933-6942.
81. Tsuji N.M., Tsutsui H., Seki E., Kuida K., Okamura H., Nakanishi K., et al. Roles of caspase-1 in Listeria infection in mice. Int Immunol 2004, 16:335-343.
82. Sansonetti P.J., Phalipon A., Arondel J., Thirumalai K., Banerjee S., Akira S., et al. Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity 2000, 12:581-590.
83. Ceballos-Olvera I., Sahoo M., Miller M.A., Del Barrio L., Re F. Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1beta is deleterious. PLoS Pathog 2011, 7:e1002452.
84. Mariathasan S., Weiss D.S., Dixit V.M., Monack D.M. Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J Exp Med 2005, 202:1043-1049.
85. Schultz M.J., Knapp S., Florquin S., Pater J., Takeda K., Akira S., et al. Interleukin-18 impairs the pulmonary host response to Pseudomonas aeruginosa. Infect Immun 2003, 71:1630-1634.
86. Schultz M.J., Rijneveld A.W., Florquin S., Edwards C.K., Dinarello C.A., van der Poll T. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung C 2002, 282:L285-L290.
87. Entezari M., Weiss D.J., Sitapara R., Whittaker L., Wargo M.J., Li J., et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med 2012, 18:477-485.
88. Gram A.M., Frenkel J., Ressing M.E. Inflammasomes and viruses: cellular defence versus viral offence. J Gen Virol 2012, 93:2063-2075.
89. Dobbelstein M., Shenk T. Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J Virol 1996, 70:6479-6485.
90. Macen J.L., Garner R.S., Musy P.Y., Brooks M.A., Turner P.C., Moyer R.W., et al. Differential inhibition of the Fas- and granule-mediated cytolysis pathways by the orthopoxvirus cytokine response modifier A/SPI-2 and SPI-1 protein. Proc Natl Acad Sci USA 1996, 93:9108-9113.
91. Gregory S.M., Davis B.K., West J.A., Taxman D.J., Matsuzawa S., Reed J.C., et al. Discovery of a viral NLR homolog that inhibits the inflammasome. Science 2011, 331:330-334.
92. Johnston J.B., Barrett J.W., Nazarian S.H., Goodwin M., Ricciuto D., Wang G., et al. A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity 2005, 23:587-598.
93. Dorfleutner A., Talbott S.J., Bryan N.B., Funya K.N., Rellick S.L., Reed J.C., et al. A shope fibroma virus PYRIN-only protein modulates the host immune response. Virus Genes 2007, 35:685-694.
94. Kanneganti T.D., Body-Malapel M., Amer A., Park J.H., Whitfield J., Franchi L., et al. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 2006, 281:36560-36568.
95. Allen I.C., Moore C.B., Schneider M., Lei Y., Davis B.K., Scull M.A., et al. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-kappaB signaling pathways. Immunity 2011, 34:854-865.
96. Zhao Q., Peng L., Huang W., Li Q., Pei Y., Yuan P., et al. Rare inborn errors associated with chronic hepatitis B virus infection. Hepatology 2012, 56:1661-1670.
97. Hong M., Yoon S.I., Wilson I.A. Structure and functional characterization of the RNA-binding element of the NLRX1 innate immune modulator. Immunity 2012, 36:337-347.
98. Sabbah A., Chang T.H., Harnack R., Frohlich V., Tominaga K., Dube P.H., et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009, 10:1073-1080.
99. Lupfer C., Thomas P.G., Anand P.K., Vogel P., Milasta S., Martinez J., et al. Receptor interacting protein kinase 2-mediated mitophagy regulates inflammasome activation during virus infection. Nat Immunol 2013, 14:480-488.
100. Tong Y., Cui J., Li Q., Zou J., Wang H.Y., Wang R.F. Enhanced TLR-induced NF-kappaB signaling and type I interferon responses in NLRC5 deficient mice. Cell Res 2012, 22:822-835.
101. Biswas A., Meissner T.B., Kawai T., Kobayashi K.S. Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator. J Immunol 2012, 189:516-520.
102. Robbins G.R., Truax A.D., Davis B.K., Zhang L., Brickey W.J., Ting J.P. Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins. J Biol Chem 2012, 287:24294-24303.
103. Cui J., Zhu L., Xia X., Wang H.Y., Legras X., Hong J., et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 2010, 141:483-496.
104. Moore C.B., Bergstralh D.T., Duncan J.A., Lei Y., Morrison T.E., Zimmermann A.G., et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 2008, 451:573-577.
105. Arnoult D., Soares F., Tattoli I., Castanier C., Philpott D.J., Girardin S.E. An N-terminal addressing sequence targets NLRX1 to the mitochondrial matrix. J Cell Sci 2009, 122:3161-3168.
106. Soares F., Tattoli I., Wortzman M.E., Arnoult D., Philpott D.J., Girardin S.E. NLRX1 does not inhibit MAVS-dependent antiviral signalling. Innate Immun 2013, 19:438-448.
107. Bortz E., Garcia-Sastre A. Predicting the pathogenesis of influenza from genomic response: a step toward early diagnosis. Genome Med 2011, 3:67.
108. Schmitz N., Kurrer M., Bachmann M.F., Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol 2005, 79:6441-6448.
109. Sergerie Y., Rivest S., Boivin G. Tumor necrosis factor-alpha and interleukin-1 beta play a critical role in the resistance against lethal herpes simplex virus encephalitis. J Infect Dis 2007, 196:853-860.
110. Piper S.C., Ferguson J., Kay L., Parker L.C., Sabroe I., Sleeman M.A., et al. The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells. PLoS One 2013, 8:e63365.
111. Kettle S., Alcami A., Khanna A., Ehret R., Jassoy C., Smith G.L. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J Gen Virol 1997, 78(Pt 3):677-685.
112. Sareneva T., Matikainen S., Kurimoto M., Julkunen I. Influenza A virus-induced IFN-alpha/beta and IL-18 synergistically enhance IFN-gamma gene expression in human T cells. J Immunol 1998, 160:6032-6038.
113. Gherardi M.M., Ramirez J.C., Esteban M. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol 2003, 84:1961-1972.
114. Liu B., Mori I., Hossain M.J., Dong L., Takeda K., Kimura Y. Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J Gen Virol 2004, 85:423-428.
115. Fujioka N., Akazawa R., Ohashi K., Fujii M., Ikeda M., Kurimoto M. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. J Virol 1999, 73:2401-2409.
116. Jacobs S.R., Damania B. NLRs, inflammasomes, and viral infection. J Leukoc Biol 2012, 92:469-477.
117. Smith V.P., Bryant N.A., Alcami A. Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J Gen Virol 2000, 81:1223-1230.
118. Boelen A., Kwakkel J., Barends M., de Rond L., Dormans J., Kimman T. Effect of lack of Interleukin-4, Interleukin-12, Interleukin-18, or the Interferon-gamma receptor on virus replication, cytokine response, and lung pathology during respiratory syncytial virus infection in mice. J Med Virol 2002, 66:552-560.
119. Hodges J.L., Ireland D.D., Reiss C.S. The role of interleukin-18 in vesicular stomatitis virus infection of the CNS. Viral Immunol 2001, 14:181-191.
120. Moisy D., Avilov S.V., Jacob Y., Laoide B.M., Ge X., Baudin F., et al. HMGB1 protein binds to influenza virus nucleoprotein and promotes viral replication. J Virol 2012, 86:9122-9133.
121. Zhang G., Kobayashi T., Kamitani W., Komoto S., Yamashita M., Baba S., et al. Borna disease virus phosphoprotein represses p53-mediated transcriptional activity by interference with HMGB1. J Virol 2003, 77:12243-12251.
122. Song M.J., Hwang S., Wong W., Round J., Martinez-Guzman D., Turpaz Y., et al. The DNA architectural protein HMGB1 facilitates RTA-mediated viral gene expression in gamma-2 herpesviruses. J Virol 2004, 78:12940-12950.
123. Costello E., Saudan P., Winocour E., Pizer L., Beard P. High mobility group chromosomal protein 1 binds to the adeno-associated virus replication protein (Rep) and promotes Rep-mediated site-specific cleavage of DNA, ATPase activity and transcriptional repression. EMBO J 1997, 16:5943-5954.
124. Mitsouras K., Wong B., Arayata C., Johnson R.C., Carey M. The DNA architectural protein HMGB1 displays two distinct modes of action that promote enhanceosome assembly. Mol Cell Biol 2002, 22:4390-4401.
125. Harrison S.M., Whitehouse A. Kaposi's sarcoma-associated herpesvirus (KSHV) Rta and cellular HMGB1 proteins synergistically transactivate the KSHV ORF50 promoter. FEBS Lett 2008, 582:3080-3084.
126. Cotmore S.F., Tattersall P. High-mobility group 1/2 proteins are essential for initiating rolling-circle-type DNA replication at a parvovirus hairpin origin. J Virol 1998, 72:8477-8484.
127. van Zoelen M.A., van der Sluijs K.F., Achouiti A., Florquin S., Braun-Pater J.M., Yang H., et al. Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009, 391:265-273.
128. Ito Y., Torii Y., Ohta R., Imai M., Hara S., Kawano Y., et al. Increased levels of cytokines and high-mobility group box 1 are associated with the development of severe pneumonia, but not acute encephalopathy, in 2009 H1N1 influenza-infected children. Cytokine 2011, 56:180-187.
129. Ivanov S., Dragoi A.M., Wang X., Dallacosta C., Louten J., Musco G., et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007, 110:1970-1981.
130. Nowak P., Barqasho B., Treutiger C.J., Harris H.E., Tracey K.J., Andersson J., et al. HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages. Cytokine 2006, 34:17-23.
131. Cassetta L., Fortunato O., Adduce L., Rizzi C., Hering J., Rovere-Querini P., et al. Extracellular high mobility group box-1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines. Aids 2009, 23:567-577.
132. Saidi H., Melki M.T., Gougeon M.L. HMGB1-dependent triggering of HIV-1 replication and persistence in dendritic cells as a consequence of NK-DC cross-talk. PLoS One 2008, 3:e3601.
133. Melki M.T., Saidi H., Dufour A., Olivo-Marin J.C., Gougeon M.L. Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk - a pivotal role of HMGB1. PLoS Pathog 2010, 6:e1000862.
134. Yanai H., Ban T., Wang Z., Choi M.K., Kawamura T., Negishi H., et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462:99-103.
135. Jung J.H., Park J.H., Jee M.H., Keum S.J., Cho M.S., Yoon S.K., et al. Hepatitis C virus infection is blocked by HMGB1 released from virus-infected cells. J Virol 2011, 85:9359-9368.
136. Sitia G., Iannacone M., Muller S., Bianchi M.E., Guidotti L.G. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007, 81:100-107.
137. Duhalde-Vega M., Retegui L.A. Uric acid and HMGB1 are involved in the induction of autoantibodies elicited in mice infected with mouse hepatitis virus A59. Autoimmunity 2011, 44:631-640.
138. Allonso D., Belgrano F.S., Calzada N., Guzman M.G., Vazquez S., Mohana-Borges R. Elevated serum levels of high mobility group box 1 (HMGB1) protein in dengue-infected patients are associated with disease symptoms and secondary infection. J Clin Virol 2012, 55:214-219.
139. Ong S.P., Lee L.M., Leong Y.F., Ng M.L., Chu J.J. Dengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells. PLoS One 2012, 7:e41932.
140. Dostert C., Guarda G., Romero J.F., Menu P., Gross O., Tardivel A., et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 2009, 4:e6510.
141. Griffith J.W., Sun T., McIntosh M.T., Bucala R. Pure hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. J Immunol 2009, 183:5208-5220.
142. Shio M.T., Eisenbarth S.C., Savaria M., Vinet A.F., Bellemare M.J., Harder K.W., et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog 2009, 5:e1000559.
143. Lima-Junior D.S., Costa D.L., Carregaro V., Cunha L.D., Silva A.L., Mineo T.W., et al. Inflammasome-derived IL-1beta production induces nitric oxide-mediated resistance to Leishmania. Nat Med 2013, 19:909-915.
144. Goncalves V.M., Matteucci K.C., Buzzo C.L., Miollo B.H., Ferrante D., Torrecilhas A.C., et al. NLRP3 controls Trypanosoma cruzi infection through a caspase-1-dependent IL-1R-independent NO production. PLoS Negl Trop Dis 2013, 7:e2469.
145. Silva G.K., Costa R.S., Silveira T.N., Caetano B.C., Horta C.V., Gutierrez F.R., et al. Apoptosis-associated speck-like protein containing a caspase recruitment domain inflammasomes mediate IL-1beta response and host resistance to Trypanosoma cruzi infection. J Immunol 2013, 191:3373-3383.
146. Kalantari P., Deoliveira R.B., Chan J., Corbett Y., Rathinam V., Stutz A., et al. Dual engagement of the NLRP3 and AIM2 Inflammasomes by plasmodium-derived hemozoin and DNA during Malaria. Cell Rep 2014, 6:196-210.
147. Kordes M., Matuschewski K., Hafalla J.C. Caspase-1 activation of interleukin-1beta (IL-1beta) and IL-18 is dispensable for induction of experimental cerebral malaria. Infect Immun 2011, 79:3633-3641.
148. Reimer T., Shaw M.H., Franchi L., Coban C., Ishii K.J., Akira S., et al. Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome. Eur J Immunol 2010, 40:764-769.
149. Silva G.K., Gutierrez F.R., Guedes P.M., Horta C.V., Cunha L.D., Mineo T.W., et al. Cutting edge: nucleotide-binding oligomerization domain 1-dependent responses account for murine resistance against Trypanosoma cruzi infection. J Immunol 2010, 184:1148-1152.
150. Witola W.H., Mui E., Hargrave A., Liu S., Hypolite M., Montpetit A., et al. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun 2011, 79:756-766.
151. Ewald S.E., Chavarria-Smith J., Boothroyd J.C. NLRP1 is an inflammasome sensor for Toxoplasma gondii. Infect Immun 2013.
152. Gov L., Karimzadeh A., Ueno N., Lodoen M.B. Human innate immunity to Toxoplasma gondii is mediated by host caspase-1 and ASC and parasite GRA15. MBio 2013, 4.
153. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995, 13:151-177.
154. Alexander J., Bryson K. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 2005, 99:17-23.
155. Alexander J., Brombacher F. T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?. Front Immunol 2012, 3:80.
156. Lehmann J., Enssle K.H., Lehmann I., Emmendorfer A., Lohmann-Matthes M.L. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000, 20:63-77.
157. Artis D., Johnson L.M., Joyce K., Saris C., Villarino A., Hunter C.A., et al. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J Immunol 2004, 172:4672-4675.
158. Xin L., Li Y., Soong L. Role of interleukin-1beta in activating the CD11c(high) CD45RB-dendritic cell subset and priming Leishmania amazonensis-specific CD4+ T cells in vitro and in vivo. Infect Immun 2007, 75:5018-5026.
159. Stager S., Maroof A., Zubairi S., Sanos S.L., Kopf M., Kaye P.M. Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells. Eur J Immunol 2006, 36:1764-1771.
160. Von Stebut E., Ehrchen J.M., Belkaid Y., Kostka S.L., Molle K., Knop J., et al. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med 2003, 198:191-199.
161. Wei X.Q., Niedbala W., Xu D., Luo Z.X., Pollock K.G., Brewer J.M. Host genetic background determines whether IL-18 deficiency results in increased susceptibility or resistance to murine Leishmania major infection. Immunol Lett 2004, 94:35-37.
162. Fernandez-Figueroa E.A., Rangel-Escareno C., Espinosa-Mateos V., Carrillo-Sanchez K., Salaiza-Suazo N., Carrada-Figueroa G., et al. Disease severity in patients infected with Leishmania mexicana relates to IL-1beta. PLoS Negl Trop Dis 2012, 6:e1533.
163. Hatzigeorgiou D.E., Geng J., Zhu B., Zhang Y., Liu K., Rom W.N., et al. Lipophosphoglycan from Leishmania suppresses agonist-induced interleukin 1 beta gene expression in human monocytes via a unique promoter sequence. Proc Natl Acad Sci USA 1996, 93:14708-14713.
164. Lefevre L., Lugo-Villarino G., Meunier E., Valentin A., Olagnier D., Authier H., et al. The C-type lectin receptors dectin-1, MR, and SIGNR3 contribute both positively and negatively to the macrophage response to Leishmania infantum. Immunity 2013, 38:1038-1049.
165. Arnoldi J., Moll H. Langerhans cell migration in murine cutaneous leishmaniasis: regulation by tumor necrosis factor alpha, interleukin-1 beta, and macrophage inflammatory protein-1 alpha. Dev Immunol 1998, 6:3-11.
166. Karam M.C., Merckbawi R., El-Kouba J.E., Bazzi S.I., Bodman-Smith K.B. In Leishmania major-induced inflammation, interleukin-13 reduces hyperalgesia, down-regulates IL-1beta and up-regulates IL-6 in an IL-4 independent mechanism. Exp Parasitol 2013, 134:200-205.
167. Voronov E., Dotan S., Gayvoronsky L., White R.M., Cohen I., Krelin Y., et al. IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice. Int Immunol 2010, 22:245-257.
168. Theodos C.M., Shankar A., Glasebrook A.L., Roeder W.D., Titus R.G. The effect of treating with anti-interleukin-1 receptor antibody on the course of experimental murine cutaneous leishmaniasis. Parasite Immunol 1994, 16:571-577.
169. Kostka S.L., Knop J., Konur A., Udey M.C., von Stebut E. Distinct roles for IL-1 receptor type I signaling in early versus established Leishmania major infections. J Invest Dermatol 2006, 126:1582-1589.
170. Sortica V.A., Cunha M.G., Ohnishi M.D., Souza J.M., Ribeiro-Dos-Santos A.K., Santos N.P., et al. IL1B, IL4R, IL12RB1 and TNF gene polymorphisms are associated with Plasmodium vivax malaria in Brazil. Malar J 2012, 11:409.
171. Ouma C., Davenport G.C., Awandare G.A., Keller C.C., Were T., Otieno M.F., et al. Polymorphic variability in the interleukin (IL)-1beta promoter conditions susceptibility to severe malarial anemia and functional changes in IL-1beta production. J Infect Dis 2008, 198:1219-1226.
172. Gyan B., Goka B., Cvetkovic J.T., Perlmann H., Lefvert A.K., Akanmori B., et al. Polymorphisms in interleukin-1beta and interleukin-1 receptor antagonist genes and malaria in Ghanaian children. Scand J Immunol 2002, 56:619-622.
173. Lyke K.E., Burges R., Cissoko Y., Sangare L., Dao M., Diarra I., et al. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004, 72:5630-5637.
174. Day N.P., Hien T.T., Schollaardt T., Loc P.P., Chuong L.V., Chau T.T., et al. The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis 1999, 180:1288-1297.
175. Chang H.R., Grau G.E., Pechere J.C. Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology 1990, 69:33-37.
176. Dimier I.H., Bout D.T. Co-operation of interleukin-1 beta and tumour necrosis factor-alpha in the activation of human umbilical vein endothelial cells to inhibit Toxoplasma gondii replication. Immunology 1993, 79:336-338.
177. Hunter C.A., Chizzonite R., Remington J.S. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol 1995, 155:4347-4354.
178. Villeret B., Brault L., Couturier-Maillard A., Robinet P., Vasseur V., Secher T., et al. Blockade of IL-1R signaling diminishes Paneth cell depletion and Toxoplasma gondii induced ileitis in mice. Am J Clin Exp Immunol 2013, 2:107-116.
179. Florez O., Zafra G., Morillo C., Martin J., Gonzalez C.I. Interleukin-1 gene cluster polymorphism in chagas disease in a Colombian case-control study. Hum Immunol 2006, 67:741-748.
180. Petersen C.A., Burleigh B.A. Role for interleukin-1 beta in Trypanosoma cruzi-induced cardiomyocyte hypertrophy. Infect Immun 2003, 71:4441-4447.
181. Fichera L.E., Albareda M.C., Laucella S.A., Postan M. Intracellular growth of Trypanosoma cruzi in cardiac myocytes is inhibited by cytokine-induced nitric oxide release. Infect Immun 2004, 72:359-363.
182. Holscher C., Kohler G., Muller U., Mossmann H., Schaub G.A., Brombacher F. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun 1998, 66:1208-1215.
183. Cummings K.L., Tarleton R.L. Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice. Infect Immun 2004, 72:4081-4089.
184. Mullen A.B., Lawrence C.E., McFarlane E., Wei X.Q., Carter K.C. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate. Immunology 2006, 119:348-354.
185. Murray H.W. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol 2005, 174:4916-4923.
186. Monteforte G.M., Takeda K., Rodriguez-Sosa M., Akira S., David J.R., Satoskar A.R. Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J Immunol 2000, 164:5890-5893.
187. Bryson K.J., Wei X.Q., Alexander J. Interleukin-18 enhances a Th2 biased response and susceptibility to Leishmania mexicana in BALB/c mice. Microbes Infect 2008, 10:834-839.
188. Wei X.Q., Leung B.P., Niedbala W., Piedrafita D., Feng G.J., Sweet M., et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol 1999, 163:2821-2828.
189. Haeberlein S., Sebald H., Bogdan C., Schleicher U. IL-18, but not IL-15, contributes to the IL-12-dependent induction of NK-cell effector functions by Leishmania infantum in vivo. Eur J Immunol 2010, 40:1708-1717.
190. Helmby H., Grencis R.K. IL-18 regulates intestinal mastocytosis and Th2 cytokine production independently of IFN-gamma during Trichinella spiralis infection. J Immunol 2002, 169:2553-2560.
191. Helmby H., Takeda K., Akira S., Grencis R.K. Interleukin (IL)-18 promotes the development of chronic gastrointestinal helminth infection by downregulating IL-13. J Exp Med 2001, 194:355-364.
192. Baratin M., Roetynck S., Lepolard C., Falk C., Sawadogo S., Uematsu S., et al. Natural killer cell and macrophage cooperation in MyD88-dependent innate responses to Plasmodium falciparum. Proc Natl Acad Sci USA 2005, 102:14747-14752.
193. Singh R.P., Kashiwamura S., Rao P., Okamura H., Mukherjee A., Chauhan V.S. The role of IL-18 in blood-stage immunity against murine malaria Plasmodium yoelii 265 and Plasmodium berghei ANKA. J Immunol 2002, 168:4674-4681.
194. Perkmann T., Winkler H., Graninger W., Kremsner P.G., Winkler S. Circulating levels of the interleukin (IL)-4 receptor and of IL-18 in patients with Plasmodium falciparum malaria. Cytokine 2005, 29:153-158.
195. Cai G., Kastelein R., Hunter C.A. Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect Immun 2000, 68:6932-6938.
196. Liu Q., Shang L., Jin H., Wei F., Zhu X.Q., Gao H. The protective effect of a Toxoplasma gondii SAG1 plasmid DNA vaccine in mice is enhanced with IL-18. Res Vet Sci 2010, 89:93-97.
197. Vossenkamper A., Struck D., Alvarado-Esquivel C., Went T., Takeda K., Akira S., et al. Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control. Eur J Immunol 2004, 34:3197-3207.
198. Muller U., Kohler G., Mossmann H., Schaub G.A., Alber G., Di Santo J.P., et al. IL-12-independent IFN-gamma production by T cells in experimental Chagas' disease is mediated by IL-18. J Immunol 2001, 167:3346-3353.
199. Bastos K.R., Barboza R., Sardinha L., Russo M., Alvarez J.M., Lima M.R. Role of endogenous IFN-gamma in macrophage programming induced by IL-12 and IL-18. J Interferon Cytokine Res 2007, 27:399-410.
200. Higgins S.J., Xing K., Kim H., Kain D.C., Wang F., Dhabangi A., et al. Systemic release of high mobility group box 1 (HMGB1) protein is associated with severe and fatal Plasmodium falciparum malaria. Malar J 2013, 12:105.
201. Angeletti D., Kiwuwa M.S., Byarugaba J., Kironde F., Wahlgren M. Elevated levels of high-mobility group box-1 (HMGB1) in patients with severe or uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2013, 88:733-735.
202. Zhao Y.O., Khaminets A., Hunn J.P., Howard J.C. Disruption of the Toxoplasma gondii parasitophorous vacuole by IFNgamma-inducible immunity-related GTPases (IRG proteins) triggers necrotic cell death. PLoS Pathog 2009, 5:e1000288.
203. Kumar K., Singal A., Rizvi M.M., Chauhan V.S. High mobility group box (HMGB) proteins of Plasmodium falciparum: DNA binding proteins with pro-inflammatory activity. Parasitol Int 2008, 57:150-157.
204. Morales M., Onate E., Imschenetzky M., Galanti N. HMG-like chromosomal proteins in Trypanosoma cruzi. J Cell Biochem 1992, 50:279-284.